Tissue factor pathway inhibitor: from unknown coagulation inhibitor to major antithrombotic principle

Transcription

1 286 Ž. Cardiovascular Research Cardiovascular Mystery Series Series Editor: Karl T. Weber Review Tissue factor pathway inhibitor: from unknown coagulation inhibitor to major antithrombotic principle Anne Karin Lindahl Department of Vascular Surgery, UniÕersity of Oslo, Aker Hospital, 0514 Oslo, Norway Received 10 May 1996; accepted 6 September 1996 Keywords: Thrombosis; Tissue factor pathway inhibitor 1. Introduction Acute thrombosis is the major immediate cause of cardiovascular death. The thrombotic process is also a stimulus for developing and continuing the atherosclerotic process. To control thrombus formation has been the aim of scientists during several decades. Exposure of tissue factor Ž TF. to blood, for instance on rupture of atherosclerotic plaques or on endothelial cell damage, may cause acute obstruction of a vessel due to thrombus formation. Thus, the physiological TF inhibitor, tissue factor pathway inhibitor Ž TFPI., is of interest both pathophysiologically and for its pharmacological potential in inhibiting TF-induced thrombus formation. Exposure of TF to circulating blood starts the coagulation cascade by binding to Factor VIIŽ.Ž a FVIIa., and the complex of FVIIa and TF activates Factor X Ž FX. and Factor IX Ž FIX.. TFPI is dependent on some degree of coagulation activation and formation of activated FX Ž FXa. in order to inhibit the FVIIarTF comple Physiologically, TFPI s main role is inhibition of small amounts of tissue factor, and this inhibition is probably essential for maintaining a normal hemostatic balance. It is not known whether total lack of this inhibitor is compatible with life, since no such deficiency has been found. Serial measurements of increasing plasma TFPI during the course of a disease may signal poor prognosis. Heparin accelerates TFPI s inhibitory effect and free TFPI has great heparin affinity. TFPI probably contributes significantly to the anticoagulant properties of the endothelium, and may be particularly important for the outcome of vascular injury. The discovery of the inhibitory principle of TFPI has opened a new arena for pharmacological intervention in the thrombotic process. This may well be a major breakthrough for the control of acute thrombosis in cardiovascular disease. Recombinant TFPI has proved effective in the treatment of experimental disseminated intravascular coagulation, sepsis and thrombosis. Whether TFPI or TFPI derivatives will be as effective in the treatment of patients remains to be determined. 2. The molecular basis of inhibition TFPI has a double inhibitory effect; it inhibits FXa 1:1 by binding at or near its active site, and it inhibits TF by forming a quaternary inhibitory complex consisting of TFPI, TF, FVIIa and FXa Ž Fig. 1.. The FXa binding is reversible and calcium-independent, while the binding of TFrF VIIa to TFPIrFXa is irreversible and calcium-dew1 3 The clue to this mechanism of inhibition is pendent that TFPI does not exert its TF-inhibiting effect unless the coagulation cascade has been activated. Once FXa has been formed, TFPI inhibits FXa, and through this binding becomes able to feedback-inactivate the TF-triggering of the coagulation through complexing with Factor VIIarTF. TFPI is a Kunitz-type serine protease inhibitor of 276 amino acids and appro 42 kda molecular weight wx 4. The complete gene structure of TFPI has been established and localized to gene 2q wx 5. TFPI has been purified from human endothelial cells and megakaryocytes, from culture supernatants of HepG2 cells and several other cancer cell lines. It has been recombinantly produced in mouse fibroblasts and baby hamster kidney cells transfected with mammalian expression plasmids as well as from yeast and E. coli. TFPI consists of three Kunitz-type structures, of which the first inhibits FXa, while the second inhibits the TFrFVIIa complex wx 6. The C-terminal region of the TFPI molecule is involved in FXa inhibition, and TFPI molecules without the C-terminal have a reduced anti-xa effect and reduced anticoagulant effect in vitro wx 7. The role of Kunitz domain 3 was until recently less understood, but there are Time for primary review 20 days r97r$17.00 Copyright q 1997 Elsevier Science B.V. All rights reserved. Downloaded from PII S Ž

2 ( ) A.K. LindahlrCardioÕascular Research Fig. 1. Feedback inhibition by TFPI. The complex of activated Factor VII Ž FVIIa. and tissue factor Ž TF. triggers coagulation by activating Factors IX and X. Once activated Factor X Ž FXa. is formed, TFPI binds and inhibits further action of FXa. The complexing of FXa with TFPI enables TFPI to bind to TFrFactor VIIa, thus making a quarternary inhibitory complex consisting of FXa, TFPI, FVIIa and TF. now indications that regions within the third domain conwx 8. Domain 3, tribute to the lipoprotein binding of TFPI and even more so the carboxyl terminus of the full-length TFPI molecule, is necessary for optimal FXa inhibition, and also for TFPI s binding to heparins wx 7. The heparininduced enhancement of TFPI s FXa-inhibition has been shown to become gradually greater as more of the C-terminal portion is intact. 3. Measurements of TFPI in health and disease Estimations based on the amount of heparin-releasable TFPI Ž see below. indicate that as much as 75 90% of total body TFPI is located in relation to the endothelial cells. The ratio between endothelium intracellular and extracellular TFPI is not known. The remaining 10 25% is found in circulating blood in two main fractions: most of it is lipoprotein-bound TFPI Ž 95%.; the smaller fraction Ž 5%. is free TFPI wx 9. Both of these fractions are measurable in TFPI assays. Functional assays, like the amidolytic assay w10 x, measures the total TFPI, while the ELISA assays can differentiate between full-length, free TFPI and lipoprow11 Coagulation assays Ž clotting assays. may best reflect the anticoagulant function of the different tein-bound TFPI TFPIs, as this mimics the in vivo coagulation and takes the kinetics of the inhibition into account w12 The mean plasma concentration of TFPI in a healthy adult population was 2.25 nm or 89 ngrml Ž95% range: ngrml. measured by an immunological method w13 The TFPI levels are lowest at birth, they increase slightly with age and there is no gender difference w10,13 Most studies of clinical materials have been performed with functional end-point assays w14,15 However, the number of reports of TFPI results using a commercially available ELISA assay is increasing w11 A third, clotting-based, dilute prothrombin time activity assay has also been used w12,16,17 Results from these three different kinds of TFPI assays are not directly comparable. Increased levels of TFPI have been observed in a number of illnesses, including malignancy and septicemia, and more recently also in uremic patients, in poorly reguw14 19 Increased plasma TFPI levels have been reported in malig- lated diabetics and in patients with hyperlipidemia nant disease and inflammatory processes also in children w20 The reason for the increased TFPI levels in these clinical situations is mostly unknown. In hyperlipidemia, it mainly reflects increased levels of its carrier, the lipoproteins. It has been shown that when LDL is lowered pharw21 In other macologically, the TFPI levels normalize clinical situations, the inflammatory process itself may be the signal for increased TFPI production. In vitro studies have earlier indicated that there might be a slight increase in TFPI produced by endothelial cells and monocytes by stimulation with endotoxin w22 However, van der Logt and co-workers did not find increased mrna or TFPI protein in isolated peripheral blood monocytes after stimuw23 The increased levels reported are only slightly lation increased compared to age-adjusted normal controls. One single measurement in a patient is difficult to interpret. However, serial TFPI plasma measurements in patients with sepsis and malignant disease have shown steadily increasing TFPI levels in patients with fatal outcome comw14,15x and serial measurements may be pared to survivors clinically useful in predicting outcome for patients with fatal illnesses. 4. Anticoagulant activity versus antigenic measurements of TFPI The full-length TFPI has more anticoagulant activity in the dilute prothrombin time assay than lipoprotein-bound or otherwise truncated TFPI w12 Accordingly, a TFPI derivative expressed in yeast, containing only the first 161 amino acids, and thus lacking the third Kunitz domain, showed similar activities to full-length TFPI toward FXarTFrFVIIa in chromogenic substrate assays with puw16 However, the anticoagulant activity in rified factors the dilute prothrombin time assay was about 50-fold lower, and comparable to the effect of antibodies to TF in the same assay w16 It is known that TFPI from different sources mammalian cell lines, normal plasma, postheparin plasma Žplasma drawn after an i.v. bolus of heparin. and plasma fractions with similar inhibitory activity in an amidolytic assay has shown significantly different anticoagulant effects in clotting assays w17 Hubbard and Weller found that the antigen methods measure up to 10 times increased levels in post-heparin plasma compared with only 2 3 times increase with a functional method w11 The difference in TFPI levels measured by the antigen assay and the functional assay may be understood if

3 288 ( ) A.K. LindahlrCardioÕascular Research TFPI antigen assay is mainly directed against domain 3, which is exposed only where the TFPI molecule is not bound to lipoprotein. Another explanation that has been advocated is that the lipoprotein somehow masks the TFPI from being detected by antigenic methods. In postheparin plasma the fraction of TFPI not bound by lipoprow17 tein increases the most 5. TFPI and plasma lipoproteins The formation of a TFPI lipoprotein complex is depenwx 8. dent on the presence of TFPI s third Kunitz domain Lesnick and co-workers found that the major plasma carriers of TFPI are small, dense subspecies of LDL, HDL and lipoprotein Ž.Ž a LpŽ.. a, whereas very-low-density lipoproteins Ž VLDL. and intermediate-density lipoproteins Ž IDL. do not seem to transport TFPI w24 TFPI in plasma is 50% associated with HDL, 40 45% associated with LDL, and about 5% is free TFPI wx 9. In patients with hypercholesterolemia treated with the cholesterol-lowering drug, simvastatin, the reduction in TFPI after treatment correlated closely with the LDL cholesterol concentration w21 In a recent study of young male survivors after myocardial infarction, the TFPI activity levels Ž amidolytic assay. were found to be increased in patients with hyperlipidemia Ž 1.25"0.23 vs. 1.17"0.20 Urml in controls., particuw25 The larly in those with type IIb hyperlipoproteinemia increase in TFPI was significantly correlated with the dense LDL apob-levels Ž r s and the small dense HDL subspecies HDL3b Ž rs The role of increased TFPI plasma level in hyperlipemic patients is unclear. It may represent an increased resistance to TF-induced coagulation, but, more likely, it may just reflect the binding of TFPI to the increased amount of lipoprotein. Lipoproteinw8,17 x, and bound TFPI is less anticoagulant than free TFPI the binding of TFPI to lipoprotein may impair the anticoagulant activity of TFPI in hyperlipidemic subjects. It remains to be investigated whether this plays a role in the pathogenesis of premature coronary disease. 6. The release of TFPI into the blood by heparin injection When heparin is injected into the blood, a rise in plasma TFPI is observed after 5 10 min w26 This release of TFPI seen on injection of unfractionated heparin and also on injection of low-molecular-weight heparin, contributes significantly to the anticoagulant effect of heparin in vitro and probably also in vivo w12,17 Other glycosaminoglycans Že.g., dermatan sulphate and pentosan polysulphate. are also able to induce TFPI release, but to a lesser extent than heparin w14 x, probably due to lower binding affinity. The binding of TFPI to heparin is dependent on the molecular mass of heparin, with a maximum over 10 kda w27 On long-term continuous heparin infuw28 The increase in sion, the TFPI levels stay elevated TFPI seems to be dose-dependent and correlates quite well with the activated partial prothrombin time Ž APTT. Žr s and anti-xa activity Ž r s w27 TFPI is most probably released from endothelial cells upon heparin infusion, although the binding sites for TFPI on the endothelial cells have not been identified. It has been suggested that TFPI is bound to endothelial cell glycosaminoglycans, especially heparan sulphate, owing to the known heparin binding of TFPI. However, a recent in vitro study found conflicting results with this hypothesis: the binding of TFPI to the endothelial cell surface was not influenced by pretreatment of the endothelial cells with glycosaminow29 On repeated heparin glycan-degrading compounds injections, repeated peaks in plasma TFPI are seen, indicating that TFPI is released into the blood by the presence of the heparin, and that most of the TFPI slips back onto the endothelium as heparin is cleared from the circulation w14 Cancer patients have an increased TFPI-releasing rew30 Kalbas and co-workers have shown that malignant HepG2 sponse to heparin injection compared with normals cells released more than 5 times the baseline value of TFPI, while human umbilical vein endothelial cells released only twice the baseline value. The release was independent of protein synthesis w31 Some patients with thrombophilia without known other cause are poor responders and release less TFPI on heparin infusion than others w28 Also, patients with poorly regulated diabetes release more TFPI on heparin injection than well-regulated diabetics w19 These studies indicate that in selected patient groups, a heparin challenge test with the measurement of releasable TFPI upon heparin injection could give valuable additional information. 7. TFPI as protection against DIC in everyday life? If the level of exposure of endotoxin or tissue factor exceeds a certain level, DIC and septic shock results. Smaller amounts of endotoxin or tissue factor will not result in DIC. However, if the normal level of TFPI is reduced, as was done by antibodies in rabbits in experimental DIC studies, the same low level of endotoxin or tissue factor resulted in fulminant DIC w32 This indicates a physiological role for TFPI in handling the levels of endotoxin or tissue factor that we may be exposed to repeatedly during minor illnesses or everyday life. 8. Blocking TFPI as hemophilia treatment Patients with hemophilia have longer dilute prothrombin times than normals, and the prolongation is normalized after treating the plasma sample with antibodies to TFPI

4 ( ) A.K. LindahlrCardioÕascular Research w33 The question of whether neutralizing TFPI would be beneficial in the treatment of hemophiliacs was addressed in a rabbit study in which antibodies against TFPI normalized the prolonged bleeding time in hemophiliac rabbits w34 Inhibiting TFPI may be a possible first aid for hemophiliacs in situations where all other therapeutic possibilities have outplayed their role. 9. Pharmacological potential of TFPI Various forms of TFPI may show different pharmacological as well as anticoagulant properties. Bregengaard and co-workers found that in rabbits the distribution volume of a full-length TFPI was about 10 times larger than for a TFPI containing only the first two Kunitz domains w35 The full-length TFPI disappeared from the circulation quickly as a result of binding to components in the vessel wall. Heparin interfered with that binding, and injection of heparin recovered the full-length TFPI, giving a release similar to vessel-wall-bound endogenous TFPI. Also, the site of interaction is probably located within the third Kunitz domain or in the C-terminus, since the two-domain TFPI was not recovered by the presence of heparin, but required lower doses to maintain the same plasma concenw35 Studies in rabbits and baboons have shown that increas- tration ing the plasma levels of TFPI by infusing recombinant TFPI in large doses protects against disseminated intravascular coagulation Ž DIC. and septic shock induced by tissue factor or E. coli w36,37 In the baboon study, pretreatment with TFPI prevented the E. coli septic shock and improved survival significantly. Also, TFPI prevented the induced septic shock and death in the baboons even when administered several hours after the E. coli infusion. Thus, TFPI effectively prevented septic shock, and was also effective in the treatment of already ongoing sepsis w TFPI as antithrombotic drug Recombinant TFPI proved effective as an antithrombotic drug in an ex vivo model of thrombogenesis on TF-containing subendothelium in the presence of both FXa and FVIIa w38 Infusion of various types of recombinant TFPI has been shown to prevent venous and arterial thrombosis in animal models w39 43 In a rabbit ear model of microvascular anastomosis, local application of TFPI increased patency rates significantly above controls Ž patency at 7 days: controls 0%, TFPI treated 73%., and patency was higher with TFPI than with heparin Žat 7 days: 73% vs. 40%. w40 Also, TFPI has been shown to prevent arterial reocclusion after thrombolytic therapy in a dog model w39 Promising results have recently been found in the baboon for the antithrombotic effect of a TFPI containing only the two first Kunitz domains w41 TFPI prevented acute arterial thrombus formation after surgical endarterectomy performed on baboon aorta which was exposed to flowing arterial blood for 60 min in a shunt model. The thrombus was 90% reduced with TFPI compared to controls, as measured with indium-labelled platelet deposition and with iodine-labelled fibrinogen. Another TF-inhibiting compound, active site inhibited FVIIa, has shown similar antithrombotic effects also on thrombus formation on in vivo surgical carotid endarterectomies w43 These studies underline the important triggering effect that TF in the subendothelium has on thrombus formation, and, extrapolating, may indicate great effects for prevention of thrombi formed on TF-rich atherosclerotic plaques upon rupture or in conjunction with interventional therapy. The long-term beneficial effect of TFPI treatment has been verified in a rabbit model of balloon angioplasty, where inhibition of tissue factor by either TFPI or an inactivated Factor FVIIa showed significant reduction of neointimal thickness after 21 days. The reduction in neointimal thickness was significant compared with controls Žminimal luminal diameter for controls, 0.88" 0.21 mm; for TFPI-treated, 1.32"0.21 mm., but also when compared with treatment with hirudin Ž 0.97" 0.22 mm., which inhibits thrombin directly, or TAP, which inhibits Factor Xa Ž 0.98"0.14 mm. w Future perspectives Inhibition of tissue factor is one of several paths for pharmaceutical intervention of the thrombotic process. It seems particularly promising for stopping processes induced by tissue damage and exposure of TF, and there is evidence that inhibition of TF is more potent than inhibition further down the coagulation cascade both for acute thrombus and for neointimal hyperplasia. However, the size of the TFPI molecule indicates that exploitation of the TF-inhibiting principle is the main gain from these discoveries, and there is a continuous search for smaller and maybe even more effective compounds. Measuring plasma TFPI is not yet routine in most hemostasis laboratories. The best method for measuring the in vivo effect of TFPI is still being debated. An elevated plasma TFPI may indicate a poor prognosis in certain patient groups, especially if found to be increasing in serial measurements. Also, the heparin challenge, the TFPI release upon heparin injection, may be useful in the investigation of thrombophilia. The results of preclinical and clinical trials of TFPI in humans are expected to bring an important new principle of inhibition of thrombus formation into everyday medical practice. If TFPI or other TF-inhibiting compounds in addition are able to inhibit the formation of neointimal hyperplasia after interventional procedures like angioplasty, stenting or surgery, a major breakthrough in reducing cardiovascular mortality and morbidity will have been made.

5 290 ( ) A.K. LindahlrCardioÕascular Research References wx 1 Rao LVM, Rapaport SI. Studies of a mechanism inhibiting the initiation of the extrinsic pathway of coagulation. Blood 1987;69: wx 2 Broze GJ, Miletich JP. Characterization of the inhibition of tissue factor in serum. Blood 1987;69: wx 3 Broze GJ, Warren LA, Novotny WF, Higuchi DA, Girard JJ, Miletich JP. The lipoprotein-associated coagulation inhibitor that inhibits the factor VIIa tissue factor complex, also inhibits factor Xa: Insight into its possible mechanism of action. Blood 1988;71: wx 4 Wun TC, Kretzmer KK, Girard TJ, Miletich JP, Broze GJ. Cloning and characterization of a cdna coding for the lipoprotein-associated coagulation inhibitor shows that it consists of three tandem Kunitztype inhibitory domains. J Biol Chem 1988;263: wx 5 Enjyouji KI, Emi E, Mukai T, et al. Human tissue factor pathway inhibitor Ž TFPI. gene: complete genomic structure and localization on the genomic map of chromosome 2q. Genomics 1993;17: wx 6 Girard TJ, Warren LA, Novotny WF, et al. Functional significance of the Kunitz-type inhibitory domains of the lipoprotein-associated coagulation inhibitor. Nature 1989;338: wx 7 Wesselschmidt R, Likert K, Huang Z, MacPhail L, Broze J Jr. Structural requirements for tissue factor pathway inhibitor interactions with factor Xa and heparin. Blood Coagul Fibrinolysis 1993;4: wx 8 Valentin S, Nordfang O, Bregengard C, Wildgoose P. Evidence that the C-terminus of tissue factor pathway inhibitor Ž TFPI. is essential for its in vitro and in vivo interaction with lipoproteins. Blood Coagul Fibrinolysis 1993;4: wx 9 Novotny WF, Girard TJ, Miletich JP, Broze GJ. Purification and characterization of the lipoprotein-associated coagulation inhibitor from human plasma. J Biol Chem 1989;264: w10x Sandset PM, Larsen ML, Abildgaard U, Lindahl AK, Ødegaard OR. Chromogenic substrate assay of extrinsic pathway inhibitor Ž EPI.: levels in the normal population and relation to cholesterol. Blood Coagul Fibrinolysis 1991;2: w11x Hubbard AR, Weller LJ, Gray E. Measurement of tissue factor pathway inhibitor in normal and post-heparin plasma. Blood Coagul Fibrinolysis 1994;5: w12x Lindahl AK, Abildgaard U, Staalesen R. The anticoagulant effect in heparinized blood and plasma resulting from interactions with extrinsic pathway inhibitor. Thromb Res 1991;64: w13x Novotny WF, Brown S, Miletich JP, Rader DJ, Broze GJ Jr. Plasma antigen levels of the lipoprotein-associated coagulation inhibitor in patient samples. Blood 1991;78: w14x Lindahl AK, Sandset PM, Abildgaard U. The present status of tissue factor pathway inhibitor. Blood Coagul Fibrinolysis 1992;3: w15x Sandset PM, Røise O, Aasen AO, Abildgaard U. Extrinsic pathway inhibitor in postoperativerposttraumatic septicaemia: increased levels in fatal cases. Haemostasis 1989;19: w16x Hamamoto T, Yamamoto M, Nordfang O, Petersen JGL, Foster DC, Kisiel W. Inhibitory properties of full-length and truncated recombinant tissue factor pathway inhibitor Ž TFPI.. J Biol Chem 1993;268: w17x Lindahl AK, Jacobsen PBJ, Sandset PM, Abildgaard U. Tissue factor pathway inhibitor with high anticoagulant activity is increased in post-heparin plasma and in plasma from cancer patients. Blood Coagul Fibrinolysis 1991;2: w18x Kario K, Matsuo T, Yamada T, Matsuo M. Increased tissue factor pathway inhibitor levels in uremic patients on regular hemodialysis. Thromb Haemostas 1994;71: w19x Leurs PB, van Oerle R, Hamulyak K, Wolffenbuttel BH. Tissue factor pathway inhibitor activity in patients with IDDM. Diabetes 1995;44; w20x Weissbach G, Harenberg J, Wendisch J, Pargac N, Thomas K. Tissue factor pathway inhibitor in infants and children. Thromb Res 1994;73: w21x Sandset PM, Lund H, Norseth J, Ose L, Abildgaard U. Treatment with HMC-CoA reductase inhibitor in hypercholesterolaemia induces changes in the components of the extrinsic coagulation system. Arterioscl Thromb 1991;11: w22x Ameri A, Kuppuswamy MN, Basu S, Bajaj SP. Expression of tissue factor pathway inhibitor by cultured endothelial cells in response to inflammatory mediators. Blood 1992;79: w23x van der Logt CPE, Dirven RJ, Reitsma PH, Bertina RM. Expression of tissue factor and tissue factor pathway inhibitor in monocytes in response to bacterial lipopolysaccharide and phorbolester. Blood Coagul Fibrinolysis 1994;5: w24x Lesnick P, Vonica A, Guerin M, Moreau M, Chapman MJ. Anticoagulant activity of tissue factor pathway inhibitor is preferentially associated with dense subspecies of LDL and HDL and with LpŽ. a. Arterioscler Thromb 1993;13: w25x Moor E, Hamsten A, Karpe F, Bavenholm P, Blomback M, Silveira A. Relationship of tissue factor pathway inhibitor activity to plasma lipoproteins and myocardial infarction at a young age. Thromb Haemostas 1994;71: w26x Sandset PM, Abildgaard U, Larsen ML. Heparin induces release of extrinsic pathway inhibitor Ž EPI.. Thromb Res 1988;50: w27x Valentin S, Larnkjer A, Østergaard P, Nielsen JI, Nordfang O. Characterization of the binding between tissue factor pathway inhibitor and glycosaminoglycans. Thromb Res 1994;75: w28x Maaoui A, Connard J, Samama MM. Tissue factor pathway inhibitor Ž TFPI. during prolonged treatments by unfractionated Ž UH. or low molecular weight heparin Ž LMWH.. Thromb Haemostas 1993;69:681Ž Abstract.. w29x Iversen N, Sandset PM, Abildgaard U, Rao V, Nordfang O. Binding of recombinant tissue factor pathway inhibitor Ž rtfpi. to endothelial cells: influence of glycosaminoglycans. Thromb Haemostas 1993;69:644Ž Abstract.. w30x Lindahl AK, Abildgaard U, Stokke G. Extrinsic pathway inhibitor after heparin injection: increased response in cancer patients. Thromb Res 1990;59: w31x Kalbas M, Hinz U, Muller-Berghaus G. Heparin-induced release of tissue factor pathway inhibitor Ž TFPI. by human endothelial and malignant cells. Thromb Haemostas 1993;69:681Ž Abstract.. w32x Sandset PM, Warn-Cramer BJ, Rao VML, Maki SL, Rapaport SI. Depletion of extrinsic pathway inhibitor Ž EPI. sensitizes rabbits to disseminated intravascular coagulation induced with tissue factor: evidence supporting a physiological role of EPI as a natural anticoagulant. Proc Natl Acad Sci USA 1991;88: w33x Nordfang O, Valentin S, Beck TC, Hedner U. Inhibition of extrinsic pathway inhibitor shortens the coagulation time of normal plasma and of hemophilia plasma. Thromb Haemostas 1991;66: w34x Erhardsen E, Ezban M, Madsen MT, et al. Blocking of tissue factor pathway inhibitor Ž TFPI. shortens the bleeding time in rabbits with antibody induced hemophilia A. Blood Coag Fibrinolysis 1995;6: w35x Bregengaard C, Nordfang O, Østergaard P, et al. Pharmacokinetics of full length and two-domain tissue factor pathway inhibitor in combination with heparin in rabbits. Thromb Haemostas 1993;70: w36x Day KC, Hoffman LC, Palmier MO, et al. Recombinant lipoprotein associated coagulation inhibitor inhibits tissue thromboplastininduced intravascular coagulation in the rabbit. Blood 1990;76: w37x Creasey AA, Chang ACK, Feigen L, Wun TC, Taylor FB, Hinshaw LB. Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock. J Clin Invest 1993;91: w38x Lindahl AK, Sandset PM, Thune-Wiiger M, Nordfang O, Sakariassen KS. Tissue factor pathway inhibitor prevents thrombus formation on procoagulant subendothelial matri Blood Coagul Fibrinolysis 1994;5:

6 ( ) A.K. LindahlrCardioÕascular Research w39x Haskel EJ, Torr SR, Day KC, et al. Prevention of arterial reocclusion after thrombolysis with recombinant lipoprotein- associated coagulation inhibitor. Circulation 1991;84: w40x Khoury RK, Koudsi B, Kaiding F, Ornberg RL, Wun TC. Prevention of thrombosis by topical application of tissue factor pathway inhibitor in a rabbit model of vascular trauma. Ann Plast Surg 1993;30: w41x Lindahl AK, Nordfang O, Wildgoose P, Kelly AB, Harker LA, Hanson SR. Antithrombotic effects of a truncated tissue factor pathway inhibitor Ž TFPI. in baboons. Thromb Haemostas 1993;69:742Ž Abstract.. w42x Holst J, Lindblad B, Bergqvist D, et al. Antithrombotic effect of a recombinant truncated tissue factor pathway inhibitor Ž TFPI 1y 161. in experimental venous thrombosis a comparison with low molecular weight heparin. Thromb Haemostas 1994;71: w43x Lindahl AK, Wildgoose P, Lumsden AB, et al. Active site-inhibited factor VIIa blocks tissue factor activity and prevents arterial thrombus formation in baboons. Circulation Ž suppl. 1993;88:I-417ŽAb- stract.. w44x Jang Y, Guzman LA, Lincoff M, et al. Influence of blockade at specific levels of the coagulation cascade on restenosis in a rabbit atherosclerotic femoral artery injury model. Circulation 1995;92: